1. Badanie fazy I nr CSL Behring CR002-1004, Double-blind, randomized placebo-controlled single-dose phase I study of the safety and tolerability of alpha1-proteinase inhibitor (human) inhalation solution (CR002) in subjects with cystic fibrosis; site coordinator and secondary investigator - status: zakończone
2. Badanie fazy III nr POET-COPD 205.389 - Effect of inhalation of tiotropium once daily 18 mcg versus salmeterol twice daily 50 mcg on time to first exacerbation in COPD patients (a randomised, double blind, double-dummy, parallel group, one year study) - status: zakończone
3. Badanie fazy Ib/II nr ISIS 183750-CS4, Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel (NSCLC) - status: zakończone